

Errata to Staines Declaration of March 6, 2018 (Exhibit 1140)

Page	Paragraph/ Footnote #	Line	Original	Change to
3	fn. 6	4th	Exhibit (2019). Cipla exclusively . . .	Exhibit (2049). Cipla exclusively . . .
4	¶4	Last	PTAB did institute on October 21, 2017.	PTAB did institute on August 21, 2017.
4	fn. 8	3rd	. . . entered on October 21, 2017, pp. 26-	. . . entered on August 21, 2017, pp. 26-
14	fn. 14	1st	Exhibit 1076 at p. 24; . . .	Exhibit 1076 at p. 26 ; . . .
16	Fn. 27	1st	See, e.g., Exhibit 1058 at p. 1; Exhibit 2067.	See, e.g., Exhibit 1058 at p. 2 ; Exhibit 2067.
20	Fn. 43	1st	<i>Graham v. John Deere, Co.</i> , 383 U.S. 1, 17-18 (1966)	<i>Graham v. John Deere, Co.</i> , 383 U.S. 1, 17-18, 36 (1966)
22	Fn. 48	5th	. . . even though has done so for prescriptions.	. . . even though he has done so for prescriptions.
23	Fn. 49	2nd	prescription growth rate based at least in part . . .	prescription growth rate based at least in part . . .
25	¶25	4th	prescriptions annual dollar sales . . .	prescriptions and annual dollar sales . . .
43	Fn. 97	3rd	above, corticosteroids are generally not used	above, oral corticosteroids are generally not used
43	Fn. 100	1st	. . . oral antihistamines were often deemed inadeq-	. . . oral antihistamines alone were often deemed inadeq-
51	Fn. 123	2nd	18-19; Exhibit 2075 at p. 2.	18-19; Exhibit 2075 at p. 2; Exhibit 1092 at pp. 46, 50.
61	Fn. 143	1st	See, e.g., Exhibit 1075 at pp. 2-3; . . .	See, e.g., Exhibit 1075 at pp. 2- 4 ; . . .
68	¶83	3rd	. . . 1) Duonase prescriptions and revenues 1) Duonase unit sales and revenues . . .
73	fn. 171	1st	. . . Exhibit 1118 at pp. 24-26. Cipla specifical-	. . . Exhibit 1118 at pp. 24-26, 36-37 . Cipla specifical-
88	¶109	2nd	. . . in the face of generic entry often by	. . . in the face of generic entry often by
90	fn. 219	2nd	Exhibit 1079 at pp. 15, 39, 56; . . .	Exhibit 1079 at pp. 15, 39, 56 ; . . .
90	Fn. 220	1st	Exhibit 2048 at pp. 131-132; Exhibit 2053 at p. 194; . . .	Exhibit 2048 at pp. 131-132 ; Exhibit 2053 at p. 194; . . .
91	Fn. 221	1st	Exhibit 2053 at pp. 131-132; Exhibit 1122 at p. 3.	Exhibit 20 48 at pp. 131-132; Exhibit 1122 at p. 3.
92	Fn. 226	1st	See, e.g., Exhibit 1082 at pp. 2, 5-6; 17-18, 78; . . .	See, e.g., Exhibit 1082 at pp. 2, 5- 7 ; 17-18, 78; . . .
95	¶114	last	reimbursement for Dymista® the applicable . . .	reimbursement for Dymista® for the applicable . . .
98	fn. 239	1st	. . . Exhibit 1089 at p. 1; Exhibit 1091 at p. 22.	. . . Exhibit 1089 at p. 2 ; Exhibit 1091 at p. 22.
98	fn. 241	1st	. . . Exhibit 1100 at pp. 6-7.	. . . Exhibit 1100 at pp. 1 , 6-7.
99	fn. 244	1st	Exhibit 1089 at p. 3; . . .	Exhibit 1089 at pp. 2-3 ; Exhibit 1069 at pp. 15, 20; Exhibit 1092 at pp. 16-17 ; . . .
99	¶120	Last	the drug.	the drug. ^{244a} New fn. 244a: Id.
100	¶121	10th	blocked from reimbursement. ²⁴⁸ It does	blocked from reimbursement. ²⁴⁸ It does not
101	fn. 251	1st	. . . Exhibit 1089 at p. 2.	. . . Exhibit 1089 at p. 2; Exhibit 1133 at p. 26.
110	fn. 275	1st	Exhibit 2064 at ¶21.	Exhibit 2064 at ¶ 21-22 .
112	fn. 279	1st	. . . Exhibit 1134 at p. 50; Exhibit	. . . Exhibit 1134 at p. 99; Exhibit 1136 at pp. 9, 25 ; Exhibit
112	fn. 280	1st	. . . Exhibit 1134 at p. 50.	. . . Exhibit 1134 at p. 99.
113	fn. 286	2nd	p. 50.	p. 99; Exhibit 1137 at p. 4.
113	fn. 289	1st	Exhibit 1135 at pp. 26; . . .	Exhibit 1135 at pp. 26; Exhibit 1136 at p. 9 ; . . .
114	fn. 290	1st	Exhibit 1138 at pp. 6, 8-10. For example, Mr.	Exhibit 1138 at pp. 6, 24-25 . For example, Mr.
116	fn. 293	1st	Exhibit 9 provides the reports these . . .	Exhibit 9 provides the reports these . . .

